{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:15:12Z","timestamp":1789578912046,"version":"build-2803163510"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endocrine-related secondary osteoporosis (ERSOP) comprises disorders in which bone fragility results from hormonal abnormalities other than age-related or menopausal hypogonadism. Its prevalence is underestimated, and timely recognition is essential because many forms improve or reverse when the underlying endocrine disturbance is corrected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This Review highlights the evolving concepts, unmet needs, and research opportunities in ERSOP, with focus on hypercortisolism, primary aldosteronism, male hypogonadism, hypercalciuria, and FGF23-dependent phosphate-wasting disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Mild autonomous cortisol secretion (MACS) is increasingly recognized as a contributor to fracture risk even at near-normal cortisol levels.<\/jats:p>\n                    <jats:p>Primary aldosteronism promotes skeletal fragility via mineralocorticoid receptor activation, oxidative stress, hypercalciuria, and secondary hyperparathyroidism.<\/jats:p>\n                    <jats:p>Male hypogonadism is a major driver of bone loss, and optimal fracture prevention may require combined hormonal and anti-osteoporotic therapy.<\/jats:p>\n                    <jats:p>Differentiating PTH-dependent from PTH-independent hypercalciuria is crucial for management.<\/jats:p>\n                    <jats:p>FGF23-mediated phosphate-wasting disorders impair mineralization and may respond to targeted therapy, including burosumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ERSOP should be considered in patients with atypical osteoporosis phenotypes, including men, younger adults, and individuals with normal BMD but fragility fractures. Optimal care requires structured endocrine assessment, correction of the primary disorder, and integration with bone-specific therapy where appropriate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1797546","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:06Z","timestamp":1776745326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Endocrine-related osteoporosis: the state of the art"],"prefix":"10.3389","volume":"17","author":[{"given":"Iacopo","family":"Chiodini","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gennari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Rendina","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Scillitani","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Ospedale \u201cCasa Sollievo della Sofferenza\u201d","place":["San Giovanni Rotondo, Foggia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vescini","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Falchetti","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae144","article-title":"Fragility fractures and cortisol secretion in patients with nonfunctioning adrenal incidentalomas","volume":"8","author":"Favero","year":"2024","journal-title":"J Endocr Soc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4177","article-title":"In postmenopausal female subjects with type 2 diabetes mellitus, vertebral fractures are independently associated with cortisol secretion and sensitivity","volume":"100","author":"Zhukouskaya","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02212-9","article-title":"Prediction of hypertension, diabetes, and fractures in eucortisolemic women by measuring parameters of cortisol milieu","volume":"68","author":"Morelli","year":"2020","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052090","article-title":"Modified cortisol circadian rhythm: The hidden toll of night-shift work","volume":"26","author":"Andreadi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12010","article-title":"Phosphorus, phosphorous, and phosphate","volume":"17","author":"Iheagwara","year":"2013","journal-title":"Hemodial Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1606","article-title":"Fibroblast growth\u00a0factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak","volume":"91","author":"Rendina","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf227","article-title":"Adrenalectomy reduces the risk of vertebral fractures in patients with mild autonomous cortisol secretion","volume":"110","author":"Morelli","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111521","article-title":"Management and medical therapy of mild hypercortisolism","volume":"22","author":"Favero","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08977194.2023.2274579","article-title":"Fibroblast growth factor 23 and its role in bone diseases","volume":"42","author":"Jurina","year":"2024","journal-title":"Growth Factors"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2495","article-title":"Association of a common variant of the NHERF1 gene with renal calcium handling and bone mineral density in humans","volume":"97","author":"Rendina","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.8.1496","article-title":"Colocalization of glucocorticoid and mineralocorticoid receptors in human bone","volume":"16","author":"Beavan","year":"2001","journal-title":"J Bone Miner Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1528","article-title":"A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis","volume":"97","author":"Rendina","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.333","article-title":"Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations","volume":"26","author":"Gupta","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00477.2004","article-title":"Loss of bone minerals and strength in rats with aldosteronism","volume":"287","author":"Chhokar","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000441-200507000-00001","article-title":"Bone loss in rats with aldosteronism","volume":"330","author":"Runyan","year":"2005","journal-title":"Am J Med Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2014.10.013","article-title":"FGF23 gene variation and its association with phosphate homeostasis and bone mineral density in Finnish children and adolescents","volume":"71","author":"Pekkinen","year":"2015","journal-title":"Bone"},{"key":"B17","article-title":"Phosphatonins: novel insights and clinical perspectives","volume":"22","author":"Mossetti","year":"2005","journal-title":"G Ital Nefrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00539","article-title":"The interplay between the renin-angiotensin-aldosterone system and parathyroid hormone","volume":"11","author":"Zheng","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000155621.10213.06","article-title":"Hyperparathyroidism and the calcium paradox of aldosteronism","volume":"111","author":"Chhokar","year":"2005","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1660","article-title":"Bone involvement in aldosteronism","volume":"27","author":"Salcuni","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B22","unstructured":""},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2399-1","article-title":"Bone health and aldosterone excess","volume":"24","author":"Ceccoli","year":"2013","journal-title":"Osteoporos Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/836529","article-title":"Bone and mineral metabolism in patients with primary aldosteronism","volume":"2014","author":"Petramala","year":"2014","journal-title":"Int J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02043","article-title":"Lower trabecular bone score in patients with primary aldosteronism: Human skeletal deterioration by aldosterone excess","volume":"103","author":"Kim","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3206","article-title":"Primary aldosteronism as a risk factor for vertebral fracture","volume":"102","author":"Notsu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac253","article-title":"Tumor-induced osteomalacia: a systematic review and individual patient\u2019s data analysis","volume":"107","author":"Rendina","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.574151","article-title":"Primary aldosteronism and bone metabolism: A systematic review and meta-analysis","volume":"11","author":"Shi","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07132-2","article-title":"Hip fractures in patients with primary aldosteronism - a Swedish nationwide study","volume":"35","author":"Gkaniatsa","year":"2024","journal-title":"Osteoporos Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","article-title":"Secondary osteoporosis","volume":"43","author":"Ebeling","year":"2022","journal-title":"Endocr Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3033","article-title":"Risk of fracture in primary aldosteronism: A population-based cohort study","volume":"32","author":"Wu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.03.039","article-title":"Fracture risk in men with congestive heart failure risk reduction with spironolactone","volume":"52","author":"Carbone","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0417","article-title":"Primary aldosteronism as a cause of secondary osteoporosis","volume":"177","author":"Salcuni","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02348-8","article-title":"Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism","volume":"69","author":"Adolf","year":"2020","journal-title":"Endocrine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1460051","article-title":"Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.10.009","article-title":"Male sexual and reproductive health-does the urologist have a role in addressing gender inequality in life expectancy","volume":"6","author":"Tharakan","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B38","unstructured":"Male hypogonadism\n          \n          \n            \n              Sizar\n              O\n            \n            \n              Leslie\n              SW\n            \n            \n              Schwartz\n              J\n            \n          \n          Treasure Island (FL)\n          StatPearls Publishing\n          StatPearls [Internet]\n          \n          2024"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.2047-2927.2012.00008.x","article-title":"Male\u00a0hypogonadism: an extended classification based on a developmental, endocrine\u00a0physiology-based approach","volume":"1","author":"Rey","year":"2013","journal-title":"Andrology"},{"key":"B40","article-title":"Disorders of the testes and male reproductive system","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"Cunningham","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158217","article-title":"Mechanisms of central hypogonadism","volume":"22","author":"Barber","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2021.11.016","article-title":"Epidemiology of male hypogonadism","volume":"51","author":"Thirumalai","year":"2022","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B43","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"Bilezikian","year":"2019"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12827","article-title":"Late-onset hypogonadism: Bone health","volume":"8","author":"Rochira","year":"2020","journal-title":"Andrology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413640","article-title":"Management of osteoporosis in men: A narrative review","volume":"22","author":"Vescini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2019.01.006","article-title":"Age-related bone loss and sarcopenia in men","volume":"122","author":"Laurent","year":"2019","journal-title":"Maturitas"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.939897","article-title":"FSH and bone: Comparison between males with central versus primary hypogonadism","volume":"13","author":"Giovanelli","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01859-7","article-title":"Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE)","volume":"45","author":"Isidori","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12770","article-title":"European Academy of Andrology (EAA) guidelines on investigation, treatment, and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology","volume":"8","author":"Corona","year":"2020","journal-title":"Andrology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporosis Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8529(02)00032-4","article-title":"Pathophysiology of calcium nephrolithiasis","volume":"9","author":"Sakhaee","year":"2011","journal-title":"Clin Rev Bone Miner Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01422.x","article-title":"Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features","volume":"257","author":"Bilezikian","year":"2005","journal-title":"J Intern Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02099-1","article-title":"Primary hyperparathyroidism, and cardiovascular risk: evolving concepts","volume":"28","author":"Silverberg","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010020186","article-title":"The regulation of parathyroid hormone secretion and synthesis","volume":"22","author":"Kumar","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199303253281203","article-title":"A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones","volume":"328","author":"Curhan","year":"1993","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)40993-1","article-title":"Idiopathic hypercalciuria","volume":"141","author":"Lemann","year":"1989","journal-title":"J Urol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2025.04.001","article-title":"Hypercalciuria: diagnosis and treatment","volume":"52","author":"Lukas","year":"2025","journal-title":"Urol Clin North Am"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.07s221","article-title":"Vitamin D toxicity, policy, and science","volume":"22","author":"Vieth","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200009000-00010","article-title":"Hypercalcemia in granulomatous disorders: a clinical review","volume":"6","author":"Sharma","year":"2000","journal-title":"Curr Opin Pulm Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.3.6457","article-title":"Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism","volume":"85","author":"Meier","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF02207242","article-title":"Immobilization osteoporosis: a review","volume":"8","author":"Minaire","year":"1989","journal-title":"Clin Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.261","article-title":"Milk-alkali syndrome","volume":"84","author":"Medarov","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2008.01.006","article-title":"Bone disease and idiopathic hypercalciuria","volume":"28","author":"Zerwech","year":"2008","journal-title":"Semin Nephrol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81778","article-title":"Idiopathic hypercalciuria: a comprehensive review of clinical insights and management strategies","volume":"17","author":"Meher","year":"2025","journal-title":"Cureus"},{"key":"B65","unstructured":"EAU Guideline Section on Urolithiasis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.05.006","article-title":"Medical management to prevent recurrent nephrolithiasis: AUA guideline (2014)","volume":"192","author":"Pearle","year":"2014","journal-title":"J Urol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2023.05.001","article-title":"Medical management of urolithiasis: great efforts\u00a0and limited progress","volume":"11","author":"Jahrreiss","year":"2024","journal-title":"Asian J Urol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2021.04.014","article-title":"Pharmacological interventions for idiopathic hypercalciuria: a systematic review","volume":"42","author":"Ferre","year":"2022","journal-title":"Nefrologia (Engl Ed)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.10.001","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.111","article-title":"Klotho, phosphate, and FGF-23 in ageing and disturbed mineral metabolism","volume":"9","author":"Kuro-o","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70298","article-title":"Phosphate in physiological and pathological mineralization: important yet often unheeded","volume":"6","author":"Qin","year":"2025","journal-title":"MedComm (2020)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02458-4","article-title":"Areas of uncertainty on the diagnosis, treatment, and follow-up of hypophosphatemia in adults: an Italian Delphi consensus","volume":"48","author":"Chiodini","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.08.035","article-title":"Evaluation of hypophosphatemia: lessons from patients with genetic disorders","volume":"59","author":"Bacchetta","year":"2012","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1797546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:09Z","timestamp":1776745329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1797546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":73,"alternative-id":["10.3389\/fendo.2026.1797546"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1797546","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1797546"}}